Home » Topics » BioWorld Science

BioWorld Science
RSS

Daiichi Sankyo presents a new orally potent analgesic, DS-54360155

Jan. 13, 2020

Novel ATX inhibitor shows promise as IOP-lowering therapy in vivo

Jan. 13, 2020

Positive results from pivotal phase II study of loncastuximab tesirine in DLBCL

Jan. 13, 2020

Nomacopan achieves primary endpoint at interim analysis of phase III CAPSTONE study

Jan. 13, 2020

Moderna begins phase II study of CMV vaccine mRNA-1647

Jan. 13, 2020

FDA clears IND for ACE-1702 for the treatment of HER2-expressing solid tumors

Jan. 13, 2020

First patient enrolled in phase I study of GEM-103

Jan. 13, 2020

FDA approves Ayvakit for unresectable or metastatic PDGFRA exon 18 mutant GIST

Jan. 10, 2020

Aclaris reports phase I data on oral MK2 inhibitor ATI-450

Jan. 10, 2020

Sellas opens enrollment in phase III trial of galinpepimut-S for AML

Jan. 10, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...